PMID- 18534873
OWN - NLM
STAT- MEDLINE
DCOM- 20091117
LR  - 20220330
IS  - 1873-2496 (Electronic)
IS  - 1078-1439 (Linking)
VI  - 27
IP  - 5
DP  - 2009 Sep-Oct
TI  - Genetic profile identification in clinically localized prostate carcinoma.
PG  - 502-8
LID - 10.1016/j.urolonc.2008.04.008 [doi]
AB  - PURPOSE: To confirm our previously obtained results, we genetically characterized 
      prostate cancer from patients undergo radical prostatectomy in a retrospective 
      study. MATERIALS AND METHODS: Histological sections were evaluated for 106 
      patients treated with surgery from 1991 to 2004. With fluorescence in situ 
      hybridization (FISH) method, the status of LPL (8p22), c-MYC (8q24) genes and 7, 
      8, X chromosomes was evaluated. RESULTS: Chromosomes 7, 8, X aneusomy was 
      demonstrated in 91.5%, 78.3%, and 51.9% of the samples, respectively, whereas LPL 
      deletion and MYC amplification were found in 76.0% and 1.6%. A genetic profile 
      was considered as unfavorable when at least two aneusomic chromosomes and one 
      altered gene were present. Tumors with an adverse genetic profile were more 
      frequently present in patients with higher stages (P = 0.02), 
      biochemical/clinical progression (P = 0.03), and Gleason grade 4 + 3 (P = 0.02). 
      Multiple correspondence analysis identified one tumor group characterized by 
      chromosome 8 aneusomy, X polysomy, LPL gene deletion, Gleason > 7 and 4 + 3 
      associated with progression. CONCLUSIONS: In this study, we recognized the 
      predictive power of previously identified cytogenetic profiles. Assessment of 
      genetic set may characterize each patient and have influence on postoperative 
      therapeutic strategies.
FAU - Gallucci, Michele
AU  - Gallucci M
AD  - Department of Urology, Regina Elena Cancer Institute, Rome, Italy.
FAU - Merola, Roberta
AU  - Merola R
FAU - Leonardo, Costantino
AU  - Leonardo C
FAU - De Carli, Piero
AU  - De Carli P
FAU - Farsetti, Antonella
AU  - Farsetti A
FAU - Sentinelli, Steno
AU  - Sentinelli S
FAU - Sperduti, Isabella
AU  - Sperduti I
FAU - Mottolese, Marcella
AU  - Mottolese M
FAU - Carlini, Paolo
AU  - Carlini P
FAU - Vico, Erika
AU  - Vico E
FAU - Simone, Giuseppe
AU  - Simone G
FAU - Cianciulli, Annamaria
AU  - Cianciulli A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080604
PL  - United States
TA  - Urol Oncol
JT  - Urologic oncology
JID - 9805460
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - EC 3.1.1.34 (Lipoprotein Lipase)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Biomarkers, Tumor/*genetics
MH  - Chromosome Aberrations
MH  - Chromosomes, Human, Pair 8/genetics
MH  - Chromosomes, Human, X/genetics
MH  - Disease Progression
MH  - Gene Dosage
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lipoprotein Lipase/genetics
MH  - Male
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Prostate-Specific Antigen/blood
MH  - Prostatic Neoplasms/*genetics/*pathology
MH  - Proto-Oncogene Proteins c-myc/genetics
MH  - Retrospective Studies
EDAT- 2008/06/07 09:00
MHDA- 2009/11/18 06:00
CRDT- 2008/06/07 09:00
PHST- 2008/02/12 00:00 [received]
PHST- 2008/03/27 00:00 [revised]
PHST- 2008/04/02 00:00 [accepted]
PHST- 2008/06/07 09:00 [pubmed]
PHST- 2009/11/18 06:00 [medline]
PHST- 2008/06/07 09:00 [entrez]
AID - S1078-1439(08)00082-3 [pii]
AID - 10.1016/j.urolonc.2008.04.008 [doi]
PST - ppublish
SO  - Urol Oncol. 2009 Sep-Oct;27(5):502-8. doi: 10.1016/j.urolonc.2008.04.008. Epub 
      2008 Jun 4.